March 2020 FDA Recall Drug by Mylan Pharmaceuticals Inc.
D-1031-2020 - Presence of particulate matter. presence of metal particles.
This Class II drug recall was voluntarily initiated by Mylan Pharmaceuticals Inc. on March 9, 2020 for the product Drug. The FDA reported the reason for recall as presence of particulate matter. presence of metal particles.. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-1031-2020
Presence of particulate matter. presence of metal particles.
03-09-2020
03-25-2020
300 100-count bottles
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Mylan Pharmaceuticals Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Distributed Nationwide in the USA
05-26-2021
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Sotalol HCL Tablets, USP (AF) 80 mg, 100 count bottles, Rx Only, Mylan Pharmaceuticals Inc. Morgantown, WV 26505 USA. NDC 00378-5123-01
Batch or Lot Expiration Information
Lot# 3095754, exp. date 02/2021